Related posts
Markets rise, but mixedThe new Biohaven began trading last October after Pfizer bought the old one only for its migraine drug. The new Biohaven is far more speculative because there are many drugs in the pipeline in early stages. They held an R&D day this week and shares soared. He has faith in their new drugs.
Biohaven Pharmaceutical is a American stock, trading under the symbol BHVN-N on the New York Stock Exchange (BHVN). It is usually referred to as NYSE:BHVN or BHVN-N
In the last year, there was no coverage of Biohaven Pharmaceutical published on Stockchase.
Biohaven Pharmaceutical was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Biohaven Pharmaceutical .
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
0 stock analysts on Stockchase covered Biohaven Pharmaceutical In the last year. It is a trending stock that is worth watching.
On 2024-11-22, Biohaven Pharmaceutical (BHVN-N) stock closed at a price of $45.57.
Shares sold off last week after the FDA refused to review one of their drugs. Could be a buying opportunity, but the company is losing money.